Clinical Trial Update: HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 1]

View source ↗

Summary

This document notes an ongoing Phase 1 trial of HS-20093 for advanced gastric and gastroesophageal junction adenocarcinoma, with recruitment currently open.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• HS-20093

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 1 | Status: RECRUITING